Furthermore, in contrast with the anti-obesity and metabolic effects of irisin [21–23], irisin has been reported to be involved in the pathogenesis of various complications of obesity, including dyslipidemia, type 2 DM, and metabolic syndrome [25,26]. This evidence concerns the gene FNDC5 and obesity due to melanocortin 4 receptor deficiency.